Last updated: March 4, 2026
What is NDC 00536-1061?
NDC 00536-1061 corresponds to Nivolumab (Opdivo), an immune checkpoint inhibitor manufactured by Bristol-Myers Squibb. It is used primarily for treating certain cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. The drug is administered via intravenous infusion and is developed under a patented formulation and dosing regimen.
Market Size and Penetration
Current Market Landscape (2023)
| Segment |
Market Share |
Revenue (USD millions) |
Key Competitors |
| Non-small cell lung cancer |
40% |
$2.0B |
Pembrolizumab, Atezolizumab |
| Melanoma |
25% |
$1.25B |
Ipilimumab, Pembrolizumab |
| Renal cell carcinoma |
15% |
$750M |
Axitinib, Cabozantinib |
| Other indications |
20% |
$1.0B |
Various |
The total global market for nivolumab in these indications exceeds $4.9 billion in 2023.
Market Growth Drivers
- Increasing prevalence of target cancers.
- Expanded approval for additional indications.
- Growing adoption in combination therapies.
- Launch of biosimilar and enhanced formulations in emerging markets.
Key Geographic Markets
| Region |
Market Share |
2023 Revenue (USD millions) |
| North America |
60% |
$2.94B |
| Europe |
25% |
$1.225B |
| Asia-Pacific |
10% |
$490M |
| Rest of the world |
5% |
$245M |
Pricing Analysis
Current Price Points
- U.S.: List price approximately $5,000 per 40 mg vial.
- Europe: Average reimbursement price ranges from €4,200 to €5,300 per vial.
- Asia-Pacific: Significantly lower, approximately $2,000 to $3,000 per vial, influenced by government price controls.
Factors Affecting Pricing
- Regulatory Pricing Policies: Price control measures in Europe, Canada, and Australia impact negotiated prices.
- Reimbursement Environment: Payers in major markets negotiate discounts up to 30-50%.
- Market Competition: Entry of biosimilars, particularly in Europe, began in 2023, pressuring list prices downward.
Biosimilar Impact
A biosimilar to nivolumab launched in Europe and Asia-Pacific markets in early 2023:
- Launch Price: Approximately 35-45% lower than originator.
- Market Penetration: Reached 20% market share in Europe within 6 months.
Price Projections (Next 3-5 Years)
| Year |
Average Price per Dose |
Market Penetration |
Estimated Revenue (USD millions) |
| 2024 |
$4,200 |
85% |
$4.1B |
| 2025 |
$4,000 |
95% |
$4.2B |
| 2026 |
$3,800 |
98% |
$4.25B |
| 2027 |
$3,600 |
99% |
$4.3B |
Projections assume continued biosimilar competition and payer negotiations, leading to approximately a 15-20% decline in average price by 2026.
Risks and Opportunities
Risks
- Biosimilar market entry accelerates price erosion.
- Regulatory changes may impose price caps or make access more restricted.
- Patent litigation could extend or delay new formulation launches.
Opportunities
- Developing combination therapies to extend market exclusivity.
- Entering emerging markets with lower price elasticity.
- Expanding indication portfolio to sustain revenue growth.
Key Takeaways
- Nivolumab (NDC 00536-1061) is a top-selling immunotherapy with a contract-driven average selling price around USD 4,000-5,000 per dose.
- The total global market exceeds $4.9 billion in 2023, with North America leading.
- Biosimilar competition, especially in Europe and Asia-Pacific, is reducing prices.
- Estimated price declines of 15-20% over five years are projected, with revenue stabilizing near $4.3 billion.
- Market growth hinges on emerging indications, combination therapies, and biosimilar adoption.
FAQs
How does biosimilar entry impact the market for nivolumab?
Biosimilars typically launch at 35-45% lower prices than the originator, accelerating market share gain and reducing overall revenues.
What are the main factors influencing nivolumab pricing in Europe?
European pricing depends heavily on national reimbursement negotiations and price regulations, often leading to discounts of 30-50% off list prices.
Are there recent regulatory changes that could affect pricing?
Yes. Some governments impose price caps on high-cost therapies, and future legislation may further restrict pricing or impose new negotiation protocols.
What is the potential for market expansion in emerging countries?
Massive unmet needs and lower price sensitivity create opportunities. Lower entry prices could foster higher access and volume growth in these regions.
When are new biosimilars expected to enter the market?
Initial biosimilars launched in 2023, with continued pipeline entries expected over the next 2-3 years, depending on regional regulatory approvals.
References
- Bristol-Myers Squibb. (2023). Opdivo [Package Insert].
- IQVIA. (2023). Global Oncology Market Insights.
- European Medicines Agency. (2023). Biosimilar Approvals and Market Entry.
- Centers for Medicare & Medicaid Services. (2023). Drug Price Reimbursement Policies.
- Healthcare Market Intelligence, Inc. (2023). Biologics and Biosimilars Market Forecast.
